JP Morgan Chase
ATYR

JP Morgan Chase’s aTyr Pharma ATYR Stock Holding History

JP Morgan Chase’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.3K Buy
150,666
+108,679
+259% +$71K ﹤0.01% 6171
2026
Q1 		$30.7K Sell
41,987
-68,386
-62% -$57.7K ﹤0.01% 6383
2025
Q4 		$86.4K Buy
110,373
+4,556
+4% +$3.74K ﹤0.01% 5968
2025
Q3 		$76.3K Buy
105,817
+64,710
+157% +$293K ﹤0.01% 6056
2025
Q2 		$208K Buy
+41,107
New +$162K ﹤0.01% 5203
2025
Q1 		– Sell
-178,532
Closed -$646K – 7812
2024
Q4 		$646K Buy
178,532
+147,092
+468% +$445K ﹤0.01% 4908
2024
Q3 		$55.3K Buy
31,440
+10,754
+52% +$19.6K ﹤0.01% 5959
2024
Q2 		$32.3K Sell
20,686
-13,168
-39% -$22.9K ﹤0.01% 6016
2024
Q1 		$66K Buy
33,854
+21,987
+185% +$38.4K ﹤0.01% 5835
2023
Q4 		$16.7K Sell
11,867
-37,775
-76% -$48.5K ﹤0.01% 6292
2023
Q3 		$78.4K Sell
49,642
-9,657
-16% -$17.9K ﹤0.01% 5626
2023
Q2 		$128K Sell
59,299
-75,569
-56% -$165K ﹤0.01% 5347
2023
Q1 		$283K Buy
134,868
+132,271
+5,093% +$290K ﹤0.01% 4841
2022
Q4 		$6K Buy
+2,597
New +$6.12K ﹤0.01% 6140
2020
Q4 		– Sell
-6
Closed – – 5984
2020
Q3 		$0 Buy
6
+1
+20% +$4 ﹤0.01% 5836
2020
Q2 		$0 Buy
+5
New +$18 ﹤0.01% 5752
2018
Q1 		– Sell
-2,151
Closed -$105K – 5663
2017
Q4 		$105K Buy
2,151
+2,022
+1,567% +$124K ﹤0.01% 4647
2017
Q3 		$9K Buy
+129
New +$5.98K ﹤0.01% 4737
2016
Q3 		– Sell
-3,087
Closed -$120K – 4856
2016
Q2 		$120K Sell
3,087
-23,545
-88% -$1.09M ﹤0.01% 3847
2016
Q1 		$1.47M Sell
26,632
-207
-0.8% -$15.7K ﹤0.01% 2865
2015
Q4 		$3.69M Buy
26,839
+827
+3% +$118K ﹤0.01% 2407
2015
Q3 		$3.74M Buy
26,012
+12,708
+96% +$2.9M ﹤0.01% 2402
2015
Q2 		$3.45M Buy
+13,304
New +$4.13M ﹤0.01% 2611

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's ATYR Position: Q2 2026 in Review

JP Morgan Chase increased its aTyr Pharma (ATYR) stake by 259% in Q2 2026, buying an estimated $71K and bringing the position to 150,666 shares worth $85.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6171.

JP Morgan Chase first reported a position in ATYR in Q2 2015 and has held it in 23 quarters since. The position peaked at $3.74M in Q3 2015. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • JP Morgan Chase held 150,666 shares of aTyr Pharma worth $85.3K as of Q2 2026.
  • JP Morgan Chase bought 108,679 aTyr Pharma shares in Q2 2026, an estimated $71K.
  • aTyr Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6171 holding.
  • JP Morgan Chase first reported a position in aTyr Pharma in Q2 2015 and has held it in 23 quarters since.
  • JP Morgan Chase's aTyr Pharma position peaked at $3.74M in Q3 2015.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.